Perceptions, attitudes, and behaviors of asthma patients towards the use of short-acting β2-agonists: A systematic review.

Autor: Loh ZC; School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor, Pulau Pinang, Malaysia., Hussain R; School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor, Pulau Pinang, Malaysia., Balan S; Pharmacy Department, Hospital Tengku Ampuan Rahimah, Klang, Selangor, Malaysia., Saini B; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia., Muneswarao J; Pharmacy Department, Hospital Pulau Pinang, George Town, Pulau Pinang, Malaysia., Ong SC; School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor, Pulau Pinang, Malaysia., Babar ZU; Department of Pharmacy, University of Huddersfield, Huddersfield, United Kingdom.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2023 Apr 20; Vol. 18 (4), pp. e0283876. Date of Electronic Publication: 2023 Apr 20 (Print Publication: 2023).
DOI: 10.1371/journal.pone.0283876
Abstrakt: Background: Short-acting β2-agonists (SABA), the most potent and rapid-acting relievers are commonly used to provide quick relief of asthma symptoms. However, there is an increasing concern regarding the misuse of SABA medicines.
Objective: This qualitative systematic review aims to determine, evaluate, and summarize the perceptions, attitudes, and behaviors towards the use of SABA from the patients' perspectives.
Methods: The databases searched included PubMed, Scopus, PsycINFO, CINAHL, and Cochrane database. Original research articles reporting the perceptions, attitudes, or behaviors of asthma patients towards the use of SABA, which was available as full text, published in the English language between the year 2000 and February 2023 were included in the review. Commentaries, letters to editor, review articles, and conference proceedings were excluded.
Results: A total of five articles were included. Six overarching themes were obtained: (1) perceptions on health status; (2) perceptions and attitudes towards the impact of asthma; (3) perceptions towards asthma control; (4) perceptions towards asthma knowledge; (5) risk perceptions; (6) perceptions, attitudes, and behaviors towards the use of SABA.
Conclusion: Despite the fact that SABA could rapidly alleviate asthma symptoms, SABA over-users were less likely to describe their health status and asthma control as 'excellent'. Most SABA over-users did not know that frequent SABA usage would worsen their asthma control, and they exhibited psychological linkage towards the use of SABA. Collaborative efforts between policymakers, healthcare professionals and patients are warranted to reconstruct SABA prescribing practice and usage.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2023 Loh et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje